Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK3.67
+0.00 (+0.00%)
SE STO Healthcare Biotechnology
Address
Medicon Village 223 63
Lund, SE
Lund, SE
CEO
Stefan Mohan Frick
Website
chemotech.se
IPO
2016-12-06
ISIN SE0009242654
Description
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
SEK3.67
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
12.4K
Beta
0.99
Float Shares
13.07M
Free Float %
54.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.51% | +0.28% | -6.43% | +3.12% | +3.70% | -21.04% | +78.43% | -17.08% | -89.65% | -92.36% | -92.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
3.67
Ratings Trend (MoM)
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.56
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+87.1% ★ Q1'26: +13.2% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+42.4% ★ Q1'26: +57.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-33.7% Q1'26: -18.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-51.3% Q1'26: -49.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -3,030.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.9% ★ Q1'26: +9.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. |
Dec 2027 1 Rev. Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
560.0K
est: 6.93M (-91.9%)
|
556.0K
est: 19.30M (-97.1%)
|
131.0K
est: 37.25M (-99.6%)
|
473.0K
est: 9.00M (-94.7%)
|
2.82M
est: 3.00M (-5.9%)
|
6.57M
est: 6.90M (-4.8%)
|
12.29M
est: 12.30M (-0.1%)
|
19.10M
19.10M – 19.10M
+55.3% YoY
|
30.60M
30.60M – 30.60M
+60.2% YoY
|
44.40M
44.40M – 44.40M
+45.1% YoY
|
| EBITDA |
-8.04M
est: -6.93M (-16.0%)
|
-11.92M
est: -19.30M (+38.3%)
|
-10.77M
est: -37.25M (+71.1%)
|
-20.81M
est: -9.00M (-131.2%)
|
-19.58M
est: -3.00M (-552.6%)
|
-12.38M
est: -6.01M (-106.1%)
|
-4.33M
est: -10.71M (+59.6%)
|
-16.63M
-16.63M – -16.63M
-55.3% YoY
|
-26.64M
-26.64M – -26.64M
-60.2% YoY
|
-38.65M
-38.65M – -38.65M
-45.1% YoY
|
| EBIT |
-8.08M
est: -6.93M (-16.7%)
|
-11.97M
est: -19.30M (+38.0%)
|
-10.83M
est: -37.25M (+70.9%)
|
-20.85M
est: -9.00M (-131.7%)
|
-19.69M
est: -3.00M (-556.3%)
|
-12.54M
est: -6.23M (-101.3%)
|
-6.30M
est: -11.10M (+43.2%)
|
-17.24M
-17.24M – -17.24M
-55.3% YoY
|
-27.62M
-27.62M – -27.62M
-60.2% YoY
|
-40.08M
-40.08M – -40.08M
-45.1% YoY
|
| Net Income |
-4.80M
|
-12.59M
est: -48.42M (+74.0%)
|
-11.66M
est: -17.56M (+33.6%)
|
-22.75M
est: -47.10M (+51.7%)
|
-21.09M
est: -26.92M (+21.6%)
|
-13.72M
est: -13.85M (+1.0%)
|
-8.06M
est: -13.85M (+41.8%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
| SGA |
6.64M
est: 615.06M (-98.9%)
|
11.73M
est: 1.71B (-99.3%)
|
6.67M
est: 3.31B (-99.8%)
|
17.86M
est: 798.89M (-97.8%)
|
19.12M
est: 266.30M (-92.8%)
|
15.41M
est: 542.26M (-97.2%)
|
—
est: 966.64M (-100.0%)
|
1.50B
1.50B – 1.50B
+55.3% YoY
|
2.40B
2.40B – 2.40B
+60.2% YoY
|
3.49B
3.49B – 3.49B
+45.1% YoY
|
| EPS |
-1.47
|
-3.06
est: -2.07 (-47.5%)
|
-2.37
est: -0.75 (-215.1%)
|
-2.28
est: -2.02 (-13.0%)
|
-1.50
est: -1.15 (-30.1%)
|
-0.59
est: -0.58 (-2.3%)
|
-0.34
est: -0.58 (+41.0%)
|
—
— – —
+100.0% YoY
|
—
— – —
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.35M
OE per share TTM
-0.19
Owner's Yield
-4.69%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-6.30M
Shares Outstanding
23.80M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ann Ohlsson | Head of Finance | — | — |
| Stefan Mohan Frick | Founder, Chief Executive Officer, President & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CMOTEC-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
